Search

Harmony Biosciences Holdings Inc

Fermé

SecteurSoins de santé

38.13 0.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

37.86

Max

38.28

Chiffres clés

By Trading Economics

Revenu

43M

75M

Ventes

46M

261M

P/E

Moyenne du Secteur

12.343

57.371

BPA

1.28

Marge bénéficiaire

28.87

Employés

293

EBITDA

53M

102M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+9.12% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

160M

2.2B

Ouverture précédente

37.58

Clôture précédente

38.13

Sentiment de l'Actualité

By Acuity

50%

50%

150 / 340 Classement par Healthcare

Harmony Biosciences Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

20 août 2026, 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

19 août 2026, 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

14 août 2026, 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

13 août 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11 août 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 août 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 août 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 août 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 août 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 août 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 août 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 août 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 juil. 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 juil. 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 juil. 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 juil. 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 juil. 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 juil. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparaison

Variation de prix

Harmony Biosciences Holdings Inc prévision

Objectif de Prix

By TipRanks

9.12% hausse

Prévisions sur 12 Mois

Moyen 41.63 USD  9.12%

Haut 55 USD

Bas 30 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

3

Achat

4

Maintien

1

Vente

Sentiment

By Acuity

150 / 340Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat